Dr. Carlsson’s area of research is focused on screening and early detection of prostate cancer. She in an investigator on the world’s largest randomized study of screening for prostate cancer, the European Randomized Study of Screening for Prostate Cancer (ERSPC). Dr. Carlsson’s research aims at finding a better balance between the harms and benefits of prostate-specific antigen (PSA) screening, through the use of multiplex testing and risk-stratified strategies that incorporates clinical information, biomarkers and magnetic resonance imaging. Her work together with Dr. Vickers on how the benefits and harms of prostate cancer screening varies by PSA levels at age 60 was published in the British Medical Journal. Dr. Carlsson is particularly interested in implementation science and implementing established knowledge into routine clinical care, including educational efforts directed at physicians and patients.